Prediction of Thorough QT Trials based on Population Pharmacokinetic: Pharmacodynamic Analysis of Phase I Study QT Data

被引：0
|
作者：
Trame, Mirjam N.
Vik, Torbjorn [1 ,2 ]
Hamren, Ulrika Wahlby [3 ]
Henriksson, Karin M. [4 ,5 ]
Friberg, Lena E.
机构：
[1] Uppsala Univ, Pharmacometr Res Grp, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] AstraZeneca R&D, AZ ECG Ctr, Molndal, Sweden
[3] AstraZeneca R&D, Clin Pharmacol & Pharmacometr, Molndal, Sweden
[4] Dept Med Sci, Uppsala, Sweden
[5] AstraZeneca R&D, Dept Epidemiol, Molndal, Sweden
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [21] Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data
    Willmann, Stefan
    Lloyd, Adam
    Austin, Rupert
    Joseph, Shiju
    Solms, Alexander
    Zhang, Yang
    Schneider, Annika R. P.
    Frechen, Sebastian
    Schultze-Mosgau, Marcus-Hillert
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (12): : 2137 - 2149
  • [22] A flexible class of models for data arising from a 'thorough QT/QTc study'
    Anand, Suraj P.
    Ghosh, Sujit K.
    PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 122 - 127
  • [23] The IQ-CSRC Prospective Clinical Phase 1 Study: "Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?"
    Darpo, Borje
    Sarapa, Nenad
    Garnett, Christine
    Benson, Charles
    Dota, Corina
    Ferber, Georg
    Jarugula, Venkateswar
    Johannesen, Lars
    Keirns, James
    Krudys, Kevin
    Ortemann-Renon, Catherine
    Riley, Steve
    Rogers-Subramaniam, Danise
    Stockbridge, Norman
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2014, 19 (01) : 70 - 81
  • [24] Results From the IQ-CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase
    Darpo, B.
    Benson, C.
    Dota, C.
    Ferber, G.
    Garnett, C.
    Green, C. L.
    Jarugula, V.
    Johannesen, L.
    Keirns, J.
    Krudys, K.
    Liu, J.
    Ortemann-Renon, C.
    Riley, S.
    Sarapa, N.
    Smith, B.
    Stoltz, R. R.
    Zhou, M.
    Stockbridge, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (04) : 326 - 335
  • [25] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF DACOMITINIB EXPOSURE ON QT INTERVALS IN PATIENTS (PTS) WITH ADVANCED NSCLC.
    Giri, N.
    Quinn, S.
    Sbar, E.
    Ruiz-Garcia, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S29 - S29
  • [26] Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients
    Fostvedt, Luke
    Shaik, Naveed
    Martinelli, Giovanni
    Wagner, Andrew
    Ruiz-Garcia, Ana
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials
    Bruno, R
    Riva, A
    Hille, D
    Lebecq, A
    Thomas, L
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 : S16 - S19
  • [28] Population Pharmacokinetic-Pharmacodynamic Analysis to Compare, the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects
    Choi, Hyang-Ki
    Jung, Jin Ah
    Fujita, Tomoe
    Amano, Hideki
    Ghim, Jong-Lyul
    Lee, Dong-Hwan
    Tabata, Kenichi
    Song, Il-Dae
    Maeda, Mika
    Kumagai, Yuji
    Mendzelevski, Boaz
    Shin, Jae-Gook
    CLINICAL THERAPEUTICS, 2016, 38 (12) : 2610 - 2621
  • [29] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Tate, Sonya C.
    Sykes, Amanda K.
    Kulanthaivel, Palaniappan
    Chan, Edward M.
    Turner, P. Kellie
    Cronier, Damien M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 335 - 344
  • [30] A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients
    Sonya C. Tate
    Amanda K. Sykes
    Palaniappan Kulanthaivel
    Edward M. Chan
    P. Kellie Turner
    Damien M. Cronier
    Clinical Pharmacokinetics, 2018, 57 : 335 - 344
12345